98 related articles for article (PubMed ID: 32410118)
1. Indicators of a pro-tumor immune response are evident at early stages of breast cancer.
Zhang C; Kurt RA
Clin Transl Oncol; 2020 Dec; 22(12):2153-2161. PubMed ID: 32410118
[TBL] [Abstract][Full Text] [Related]
2. [Tumor-induced immunosuppression in breast cancer patients].
Kharkevich DD; Polevaia EB; Kadagidze ZG
Eksp Onkol; 1990; 12(5):53-6. PubMed ID: 2226260
[TBL] [Abstract][Full Text] [Related]
3. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
[TBL] [Abstract][Full Text] [Related]
5. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome.
Huang Y; Ma C; Zhang Q; Ye J; Wang F; Zhang Y; Hunborg P; Varvares MA; Hoft DF; Hsueh EC; Peng G
Oncotarget; 2015 Jul; 6(19):17462-78. PubMed ID: 25968569
[TBL] [Abstract][Full Text] [Related]
6. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
7. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA
J Immunol; 2006 Dec; 177(11):8191-201. PubMed ID: 17114496
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated macrophage polarization promotes the progression of esophageal carcinoma.
Yuan X; Li Y; Zhang AZ; Jiang CH; Li FP; Xie YF; Li JF; Liang WH; Zhang HJ; Liu CX; Pang LJ; Shen XH; Li F; Hu JM
Aging (Albany NY); 2020 Dec; 13(2):2049-2072. PubMed ID: 33323552
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.
Gómez-Aleza C; Nguyen B; Yoldi G; Ciscar M; Barranco A; Hernández-Jiménez E; Maetens M; Salgado R; Zafeiroglou M; Pellegrini P; Venet D; Garaud S; Trinidad EM; Benítez S; Vuylsteke P; Polastro L; Wildiers H; Simon P; Lindeman G; Larsimont D; Van den Eynden G; Velghe C; Rothé F; Willard-Gallo K; Michiels S; Muñoz P; Walzer T; Planelles L; Penninger J; Azim HA; Loi S; Piccart M; Sotiriou C; González-Suárez E
Nat Commun; 2020 Dec; 11(1):6335. PubMed ID: 33303745
[TBL] [Abstract][Full Text] [Related]
11. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
12. Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models.
Gad E; Rastetter L; Slota M; Koehnlein M; Treuting PM; Dang Y; Stanton S; Disis ML
Breast Cancer Res Treat; 2014 Dec; 148(3):501-10. PubMed ID: 25395320
[TBL] [Abstract][Full Text] [Related]
13. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
[TBL] [Abstract][Full Text] [Related]
15. Higher densities of tumour-infiltrating lymphocytes and CD4
Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
[TBL] [Abstract][Full Text] [Related]
16. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
17. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
Mylvaganam G; Yanez AG; Maus M; Walker BD
Front Immunol; 2019; 10():2109. PubMed ID: 31552045
[TBL] [Abstract][Full Text] [Related]
18. TFEB is a master regulator of tumor-associated macrophages in breast cancer.
Li Y; Hodge J; Liu Q; Wang J; Wang Y; Evans TD; Altomare D; Yao Y; Murphy EA; Razani B; Fan D
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487570
[TBL] [Abstract][Full Text] [Related]
19. Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells.
Reiman JM; Knutson KL; Radisky DC
Cancer Res; 2010 Apr; 70(8):3005-8. PubMed ID: 20395197
[TBL] [Abstract][Full Text] [Related]
20. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]